MET MetLife
Sticky group-benefits franchise with disciplined buybacks; moat is real but thin
The business
MetLife collects premiums on life, group health, and annuity products, invests the float in fixed-income and alternative assets, and profits from the spread between investment returns and claims plus expenses. Group Benefits (employer-sponsored life, dental, disability) is its largest and most stable segment; international (Asia, Latin America) provides growth optionality. The business is understandable at the model level but actuarial reserve adequacy and a $300B+ investment portfolio introduce meaningful analytical complexity.
Quality gate · 68/100
Moat & management
| Moat | narrow moat |
| Source | switching costs |
| Trajectory | stable |
| Management | excellent |
Group benefits are deeply embedded in employer HR infrastructure — mid-contract switching is disruptive and rare, creating genuine stickiness. Brand longevity (150+ years) and scale provide actuarial data advantages and distributor relationships that smaller rivals can't replicate cheaply. However, life and annuity products are largely commoditized on price, InsurTech is nibbling at distribution, and there is no pricing power in the classic sense; underwriting margins are thin and cyclical.
The -5.6% annual share-count reduction over five years is exceptional and owner-friendly; management is buying back stock at scale rather than empire-building. The 2017 Brighthouse spin-off shed the most capital-intensive, volatile variable-annuity tail risk — a strategically disciplined move that most large insurers avoided making.
Owner-earnings inputs
| Owner earnings (TTM) | 3.62B |
| Owner-earnings yield | 6.6% |
| Free-cash-flow yield | 28.5% |
| Growth used (normalized) | 5.0% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 7.9% |
Key risks
- Interest-rate whipsaw: a sustained low-rate environment compresses reinvestment yields on the multi-hundred-billion investment portfolio, squeezing spread income structurally
- Actuarial tail: a pandemic, longevity shock, or adverse reserve development on legacy long-term care or variable-annuity blocks could require sudden large reserve strengthening
- Regulatory capital creep: Solvency II-style global capital standards or designation as a systemically important insurer would constrain buyback capacity and depress returns on equity
Catalysts
- Continued aggressive buybacks at current discount to intrinsic value shrink the float and compound per-share value even with flat aggregate earnings
- Asia and emerging-market middle-class expansion in underpenetrated life insurance markets could deliver above-average premium growth for a decade
Recent news
score · 8 articles
- 1 Momentum Stock for Long-Term Investors and 2 We Brush Off
- Can Trupanion Turn Pet Insurance Loyalty Into Real Earnings?
- MetLife (MET) Stock And The Valuation Puzzle After Strong Multi‑Year Gains
- Financial Stocks Are Trying to Break Out. What They Need Now—and How to Invest.
- MetLife Expands Settlement Offerings With New Flex Agreement And Valuation Upside
- World Cup Matches in US Face Heat Advisories, Storm Threats
- NJ, NYC residents brace for influx of World Cup travelers
- MetLife Broadens Settlement Solutions Portfolio With NQA-FA
⚠ financial — owner earnings ≈ net income · financial — valued by residual income (ROE vs cost of equity on book equity)